Our Company

Our mission is to develop innovative cellular therapies to transform cancer treatment worldwide​.

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT’s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer.​

Corporate Milestones

Founded to develop iPSC (induced pluripotent stem cells) technology

  • Established a well-trained R&D team in cell engineering
  • Experienced in sophisticated technologies, including iPSC, lentiviral vectors, and gene editing

Shifted to CAR-T cells technology

  • ICT’s first CAR-T product to treat ALL in a human IRB1 approved trial with 39 patients achieved 85% CR in 2015
  • Accumulated experiences in liquid tumor CAR-T that helped development of solid tumor CAR-T technology platform

Focused on solid tumor CAR-T

  • Rapid CoupledCAR® technology improvements after the first solid tumor trial started in 2017
  • Objective responses achieved in thyroid cancer and colorectal cancer from 2019

Transformed to a US focused company

  • Established operations in the U.S. in 2018 followed by opening of Global HQ in Rockville, MD in 2019
  • Obtained U.S. IND clearance for CoupledCAR® colorectal cancer program in August 2021

1Hospital institutional review board approved human proof-of-concept trials, which is one of the regulatory pathways for CAR-T in China.​